FDA approves Genglycos gene therapy
Analysis based on 6 articles · First reported Aug 20, 2026 · Last updated Aug 29, 2026
The approval provides Ultragenyx with a new revenue-generating product for an ultra-rare disease, potentially boosting its commercial prospects and stock valuation. It also validates the gene therapy platform and may positively influence investor sentiment in the rare disease gene therapy sector.
The U.S. United States — Food and Drug Administration granted accelerated approval to Ultragenyx's Genglycos (pariglasgene brecaparvovec-opnr), the first therapy for glycogen storage disease type Ia (GSDIa), a rare genetic metabolic disorder. The one-time AAV8-based gene therapy delivers a functional G6PC gene to the liver to restore glucose-6-phosphatase enzyme activity. Approval was based on the phase 3 GlucoGene trial showing a 31% greater reduction in daily cornstarch intake versus placebo at 48 weeks. The therapy is indicated for adults and children aged 8 and older as an adjunct to nutritional management. Serious adverse reactions included anaphylaxis, adrenal insufficiency, high lactate, and hypoglycemia; common side effects included elevated liver enzymes, nausea, headache, constipation, and hyperglycemia. Ultragenyx must complete confirmatory trials and provide postmarketing data through a disease monitoring program.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard